Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study

被引:72
作者
von Ahsen, N
Armstrong, VW
Behrens, C
von Tirpitz, C
Stallmach, A
Herfarth, H
Stein, J
Bias, P
Adler, G
Shipkova, M
Oellerich, M
Kruis, W
Reinshagen, M
机构
[1] Univ Gottingen, Dept Clin Chem, D-37099 Gottingen, Germany
[2] Merckle GmbH, Clin Res & Dev, Ulm, Germany
[3] Univ Ulm, Dept Med 1, Ulm, Germany
[4] Univ Saarland, Dept Internal Med 2, D-6650 Homburg, Germany
[5] Univ Regensburg, Dept Med 1, D-8400 Regensburg, Germany
[6] Univ Frankfurt, ZAFES, Dept Med 1, D-6000 Frankfurt, Germany
[7] Katharinen Hosp, Inst Clin Chem & Lab Med, D-70174 Stuttgart, Germany
[8] Univ Cologne, Evangel Krankenhaus Kalk, Cologne, Germany
[9] Klinikum Braunschweig, Dept Med 1, Braunschweig, Germany
关键词
D O I
10.1373/clinchem.2005.057158
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Azathioprine (aza) therapy is beneficial in the treatment of inflammatory bowel disease, but 10%30% of patients cannot tolerate aza therapy because of adverse drug reactions. Thiopurine S-methyltransferase (TPMT) deficiency predisposes to myelotoxicity, but its association with other side effects is less clear. Inosine triphosphatase UTPA) mutations are other pharmacogenetic polymorphisms possibly involved in thiopurine metabolism and tolerance. Methods: We analyzed data from a 6-month prospective study including 71 patients with Crohn disease undergoing first-time aza treatment with respect to aza intolerance. Patients were genotyped for common TPMT and ITPA mutations and had pretherapy TPMT activity measured. Results: Early drop-out (within 2 weeks) from aza therapy was associated with ITPA 94C > A [P = 0.020; odds ratio (OR), 4.6; 95% confidence interval (95% CI), 1.2-17.4] and low TPMT activity [< 10 nmol/(mL erythrocytes - h); P = 0.007; OR = 5.5; 95% Cl, 1.6-19.21. A high-risk group defined by ITPA 94C > A or TPMT < 10 nmol/(mL erythrocytes - h) showed significant association with early drop-out (P = 0.001; OR = 11.3; 95% CI, 2.5-50.0) and all drop-outs (P = 0.002; OR = 4.8; 95% CI, 1.8-13.3). For only drop-outs attributable to azarelated side effects (n = 16), there was a significant association with ITPA 94C > A (P = 0.002; OR = 7.8; 95% CI, 2.1-29.1). Time-to-event analysis over the 24-week study period revealed a significant association (P = 0.0311 between the time to drop-out and ITPA 94C > A mutant allele carrier status. Conclusions: Patients with ITPA 94C > A mutations or low TPMT activity constitute a pharmacogenetic high-risk group for drop-out from aza therapy. ITPA 94C > A appears to be a promising marker indicating predisposition to aza intolerance. (c) 2005 American Association for Clinical Chemistry.
引用
收藏
页码:2282 / 2288
页数:7
相关论文
共 53 条
[1]   ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression [J].
Allorge, D ;
Hamdan, R ;
Broly, F ;
Libersa, C ;
Colombel, JF .
GUT, 2005, 54 (04) :565-565
[2]  
[Anonymous], THER DRUG MONIT
[3]   Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease [J].
Ansari, A ;
Hassan, C ;
Duley, J ;
Marinaki, A ;
Shobowale-Bakre, EM ;
Seed, P ;
Meenan, J ;
Yim, A ;
Sanderson, J .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (10) :1743-1750
[4]   Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: A tertiary referral center experience [J].
Bajaj, JS ;
Saeian, K ;
Varma, RR ;
Franco, J ;
Knox, JF ;
Podoll, J ;
Emmons, J ;
Levy, M ;
Binion, DG .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (05) :1121-1125
[5]   SIGNIFICANCE TESTS FOR 2X2 TABLES [J].
BARNARD, GA .
BIOMETRIKA, 1947, 34 (1-2) :123-138
[6]   The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy [J].
Boulton-Jones, JR ;
Pritchard, K ;
Mahmoud, AA .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (12) :1561-1565
[7]   Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation [J].
Breen, DP ;
Marinaki, AM ;
Arenas, M ;
Hayes, PC .
LIVER TRANSPLANTATION, 2005, 11 (07) :826-833
[8]   Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine [J].
Campbell, S ;
Kingstone, K ;
Ghosh, S .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (03) :389-398
[9]   Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy [J].
Colombel, JF ;
Ferrari, N ;
Debuysere, H ;
Marteau, P ;
Gendre, JP ;
Bonaz, B ;
Soulé, JC ;
Modgliani, R ;
Touze, Y ;
Catala, P ;
Libersa, C ;
Broly, F .
GASTROENTEROLOGY, 2000, 118 (06) :1025-1030
[10]   Interaction between azathioprine and aminosalicylates:: an in vivo study in patients with Crohn's disease [J].
Dewit, O ;
Vanheuverzwyn, R ;
Desager, JP ;
Horsmans, Y .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (01) :79-85